Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ségolène Claeyssens‐Donadel"'
Autor:
Annelies Nijdam, Carmen Altisent, Manuel D. Carcao, Ana R. Cid, Ségolène Claeyssens-Donadel, Karin Kurnik, Rolf Ljung, Beatrice Nolan, Pia Petrini, Helen Platokouki, Anne Rafowicz, Angela E. Thomas, Kathelijn Fischer
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Externí odkaz:
https://doaj.org/article/0fc9dbf7563d408181989c0343f7738b
Autor:
Alexis Barranca, Sébastien Debarbieux, Emmanuelle Tancrède‐Bohin, Clémence Saillard, Bruno Sassolas, Sophie Voisin, Françoise Fortenfant, Chloe Bost, Ségolène Claeyssens‐Donadel, Pascal Joly, Christophe Bedane, Cristina Bulai‐Livideanu, Carle Paul, Maria Polina Konstantinou
Publikováno v:
British Journal of Dermatology. 186:899-902
Autor:
Alexis Barranca, Sébastien Debarbieux, Emmanuelle Tancrede-Bohin, Clémence Saillard, Bruno Sassolas, Sophie Voisin, Françoise Fortenfant, Ségolène Claeyssens-Donadel, Pascal Joly, Maëlla Severino-Freire, Cristina Bulai Livideanu, Carle Paul, Maria Polina Konstantinou
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A227
Autor:
Marc Trossaert, Ségolène Claeyssens-Donadel, Thierry Lambert, Chantal Rothschild, Annie Borel-Derlon, Sepideh Attal, Fabienne Volot
Publikováno v:
Transfusion. 57:1066-1071
BACKGROUND Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007. STUDY DESIGN AND METHODS This postmarketing study, as reco
Autor:
Noémie Resseguier, Natacha Rosso-Delsemme, Any Beltran Anzola, Karine Baumstarck, Vanessa Milien, Laurent Ardillon, Sophie Bayart, Claire Berger, Marie-Anne Bertrand, Christine Biron-Andreani, Annie Borel-Derlon, Sabine Castet, Pierre Chamouni, Ségolène Claeyssens Donadel, Emmanuelle De Raucourt, Dominique Desprez, Céline Falaise, Birgit Frotscher, Valérie Gay, Jenny Goudemand, Yves Gruel, Benoît Guillet, Annie Harroche, Abel Hassoun, Yoann Huguenin, Thierry Lambert, Aurélien Lebreton, Anne Lienhart, Michèle Martin, Sandrine Meunier, Fabrice Monpoux, Guillaume Mourey, Claude Negrier, Philippe Nguyen, Placide Nyombe, Caroline Oudot, Brigitte Pan-Petesch, Benoît Polack, Anne Rafowicz, Antoine Rauch, Delphine Rivaud, Pascale Schneider, Alexandra Spiegel, Cecile Stoven, Brigitte Tardy, Marc Trossaërt, Jean-Baptiste Valentin, Stéphane Vanderbecken, Fabienne Volot, Annelise Voyer-Ebrard, Bénédicte Wibaut, Tanguy Leroy, Thomas Sannie, Hervé Chambost, Pascal Auquier
Publikováno v:
BMJ Open
BMJ Open, 2018, 8 (7), pp.e022409. ⟨10.1136/bmjopen-2018-022409⟩
BMJ Open, BMJ Publishing Group, 2018, 8 (7), pp.e022409. ⟨10.1136/bmjopen-2018-022409⟩
BMJ Open, 2018, 8 (7), pp.e022409. ⟨10.1136/bmjopen-2018-022409⟩
BMJ Open, BMJ Publishing Group, 2018, 8 (7), pp.e022409. ⟨10.1136/bmjopen-2018-022409⟩
IntroductionSevere haemophilia is a rare disease characterised by spontaneous bleeding from early childhood, which may lead to various complications, especially in joints. It is nowadays possible to avoid these complications thanks to substitutive th
Autor:
V. Roussel-Robert, Christine Vinciguerra, Claude Negrier, Nicolas Chatron, Damien Sanlaville, Ségolène Claeyssens-Donadel, Mathilde Fretigny, Hervé Chambost, Yohann Jourdy, M. L. Carage
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 23(4)
Background Genomic inversions are usually balanced, but unusual patterns have been described in haemophilia A (HA) patients for intron 22 (Inv22) and intron 1 (Inv1) inversions leading to the hypothesis of more complex rearrangements involving deleti
Autor:
Thierry, Lambert, Chantal, Rothschild, Fabienne, Volot, Annie, Borel-Derlon, Marc, Trossaërt, Ségolène, Claeyssens-Donadel, Sepideh, Attal
Publikováno v:
Transfusion. 57(4)
Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007.This postmarketing study, as recommended by the risk management plan,
Autor:
A. Nijdam, Krista Fischer, Angela Thomas, Manuel Carcao, Ségolène Claeyssens-Donadel, Beatrice Nolan, Helen Platokouki, Carmen Altisent, Anne Rafowicz, Ana Rosa Cid, Karin Kurnik, Rolf Ljung, Pia Petrini
Publikováno v:
Haematologica, 100(3), e84. Ferrata Storti Foundation
Prophylaxis for hemophilia is the scheduled infusion of the missing clotting factor with pre-specified dose, with the intention of preventing bleeds and subsequent hemophilic arthropathy. It is the treatment of choice for patients with severe hemophi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7c4bac1b149d9dd505d5ffdc0c7ef07
https://europepmc.org/articles/PMC4349283/
https://europepmc.org/articles/PMC4349283/